person · Reporting owner
DiVincenzo Jonathan P.
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-RAD LABORATORIES, INC.BIO BIO.B · Entity 2247 | President & COO | September 04, 2026 | September 09, 2026 |
| LABCORP HOLDINGS INC.LH · Entity 1277 | EVP, Pres, Central Labs & Intl | March 27, 2024 | March 29, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-RAD LABORATORIES, INC.
Report date September 04, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Bio-Rad A Common StockSEC Table I · non-derivative | Direct | 1,963 |
Ending reported balance
After 2026-09-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-05 · Exercise / conversion · Acquired 1,712 · Balance 2,631 F1: Shares of Class A common stock acquired on the vesting of restricted stock units. Row 2 · 2026-09-05 · Tax withholding · Disposed 668 · Balance 1,963 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 6,326 |
Reported balance
After 2026-09-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-04 · Grant · Acquired 6,326 · Balance 6,326 F2: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3: The restricted stock units vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining units vesting in equal quarterly installments thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 5,138 |
Reported balance
After 2026-09-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-05 · Exercise / conversion · Disposed 1,712 · Balance 5,138 F2: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of Class A common stock acquired on the vesting of restricted stock units.
F2: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
F3: The restricted stock units vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining units vesting in equal quarterly installments thereafter.
F4: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
LABCORP HOLDINGS INC.
Report date March 27, 2024 · Filed March 29, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,460.5491 |
Ending reported balance
After 2024-03-27 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-03-27 · Exercise / conversion · Acquired 3,012 · Balance 6,412.5491 F1: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock. Row 2 · 2024-03-27 · Tax withholding · Disposed 952 · Balance 5,460.5491 F2: Stock withholding to satisfy tax withholding obligations. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 1,965 |
Reported balance
After 2024-03-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-27 · Exercise / conversion · Disposed 3,012 · Balance 1,965 F1: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock. F3: As previously reported, in connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Labcorp, performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting RSUs of Labcorp pursuant to the terms of the Employee Matters Agreement (the "EMA") by and between Labcorp and Fortrea. The 2021 PSA was converted into a number of time-vesting Labcorp RSUs, based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the final adjustment ratio applied to Labcorp equity awards in connection with the Spin-Off, calculated pursuant to the terms of the EMA, which fully vested on March 27, 2024. F4: This number reflects the aggregate number of RSUs held by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock.
F2: Stock withholding to satisfy tax withholding obligations.
F3: As previously reported, in connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Labcorp, performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting RSUs of Labcorp pursuant to the terms of the Employee Matters Agreement (the "EMA") by and between Labcorp and Fortrea. The 2021 PSA was converted into a number of time-vesting Labcorp RSUs, based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the final adjustment ratio applied to Labcorp equity awards in connection with the Spin-Off, calculated pursuant to the terms of the EMA, which fully vested on March 27, 2024.
F4: This number reflects the aggregate number of RSUs held by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 05, 2026 Filed Sep 9, 2026 22:45 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 1,712 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001453524-26-000002 · wk-form4_1788993926.xml · derivative · entry 4 DiVincenzo Jonathan P. · CIK 0001453524 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,138 Underlying: Bio-Rad A Common Stock · 1,712 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F4 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 05, 2026 Filed Sep 9, 2026 22:45 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 668 | $386.11 | $257,921.48 |
DisclosureSEC source: 0001453524-26-000002 · wk-form4_1788993926.xml · nonDerivative · entry 2 DiVincenzo Jonathan P. · CIK 0001453524 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,963 Read SEC document |
| September 05, 2026 Filed Sep 9, 2026 22:45 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 1,712 | $0.00 | $0.00 |
DisclosureSEC source: 0001453524-26-000002 · wk-form4_1788993926.xml · nonDerivative · entry 1 DiVincenzo Jonathan P. · CIK 0001453524 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 04, 2026 Filed Sep 9, 2026 22:45 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | GrantRestricted Stock Units · Derivative | 6,326 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001453524-26-000002 · wk-form4_1788993926.xml · derivative · entry 3 DiVincenzo Jonathan P. · CIK 0001453524 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,326 Underlying: Bio-Rad A Common Stock · 6,326 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining units vesting in equal quarterly installments thereafter. F3 · derivative.expiration_date: The restricted stock units vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining units vesting in equal quarterly installments thereafter. Read SEC document |
| October 24, 2025 Filed Oct 28, 2025 16:29 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionRestricted Stock Units · Derivative | 1,869 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001453524-25-000007 · wk-form4_1761668981.xml · derivative · entry 3 DiVincenzo Jonathan P. · CIK 0001453524 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,609 Underlying: Bio-Rad A Common Stock · 1,869 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F3 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| October 24, 2025 Filed Oct 28, 2025 16:29 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Tax withholdingBio-Rad A Common Stock | 950 | $339.75 | $322,762.50 |
DisclosureSEC source: 0001453524-25-000007 · wk-form4_1761668981.xml · nonDerivative · entry 2 DiVincenzo Jonathan P. · CIK 0001453524 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 919 Read SEC document |
| October 24, 2025 Filed Oct 28, 2025 16:29 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | Exercise / conversionBio-Rad A Common Stock | 1,869 | $0.00 | $0.00 |
DisclosureSEC source: 0001453524-25-000007 · wk-form4_1761668981.xml · nonDerivative · entry 1 DiVincenzo Jonathan P. · CIK 0001453524 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 05, 2025 Filed Sep 9, 2025 20:21 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | GrantRestricted Stock Units · Derivative | 6,850 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001453524-25-000004 · wk-form4_1757449290.xml · derivative · entry 1 DiVincenzo Jonathan P. · CIK 0001453524 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,850 Underlying: Bio-Rad A Common Stock · 6,850 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F2 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:48 UTC | BIO-RAD LABORATORIES, INC. BIO BIO.B · Entity 2247 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,863 | $0.00 Strike: $256.45 | $0.00 |
DisclosureSEC source: 0001062993-25-004589 · form4.xml · derivative · entry 1 DiVincenzo Jonathan P. · CIK 0001453524 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,863 Underlying: Bio-Rad A Common Stock · 4,863 shares Expires 2035-03-03 F1 · derivative.exercise_date: The stock option vests over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| October 24, 2024 Filed Oct 25, 2024 23:33 UTC | BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247 | GrantRestricted Stock Units · Derivative | 7,478 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-017972 · form4.xml · derivative · entry 1 DiVincenzo Jonathan P. · CIK 0001453524 · President & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,478 Underlying: Bio-Rad A Common Stock · 7,478 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F2 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 21:15 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 3,012 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000920148-24-000021 · primary_doc.xml · derivative · entry 3 DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,965 Underlying: Common Stock · 3,012 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock. F1 · price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock. F3 · derivative.exercise_date: As previously reported, in connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Labcorp, performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting RSUs of Labcorp pursuant to the terms of the Employee Matters Agreement (the "EMA") by and between Labcorp and Fortrea. The 2021 PSA was converted into a number of time-vesting Labcorp RSUs, based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the final adjustment ratio applied to Labcorp equity awards in connection with the Spin-Off, calculated pursuant to the terms of the EMA, which fully vested on March 27, 2024. F3 · derivative.expiration_date: As previously reported, in connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Labcorp, performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting RSUs of Labcorp pursuant to the terms of the Employee Matters Agreement (the "EMA") by and between Labcorp and Fortrea. The 2021 PSA was converted into a number of time-vesting Labcorp RSUs, based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the final adjustment ratio applied to Labcorp equity awards in connection with the Spin-Off, calculated pursuant to the terms of the EMA, which fully vested on March 27, 2024. F4 · balance_after: This number reflects the aggregate number of RSUs held by the reporting person. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 21:15 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 952 | $216.57 | $206,174.64 |
DisclosureSEC source: 0000920148-24-000021 · primary_doc.xml · nonDerivative · entry 2 DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,460.5491 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 21:15 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 3,012 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000920148-24-000021 · primary_doc.xml · nonDerivative · entry 1 DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,412.5491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive one share of Laboratory Corporation of America Holdings ("Labcorp") Common Stock. Read SEC document |
| February 21, 2024 Filed Feb 22, 2024 20:04 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 500 | $215.49 | $107,745.05 |
DisclosureSEC source: 0001127602-24-006252 · form4.xml · nonDerivative · entry 1 DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,400.5491 F1 · price: The price of $215.4901 per share represents a weighted average of sales prices ranging from $215.46 to $215.55 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a securityholder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| February 12, 2024 Filed Feb 13, 2024 17:15 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 59 | $227.45 | $13,419.55 |
DisclosureSEC source: 0001127602-24-004641 · form4.xml · nonDerivative · entry 2 DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,900.5491 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 11, 2024 Filed Feb 13, 2024 17:15 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 201 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004641 · form4.xml · derivative · entry 3 DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,977 Underlying: Common Stock · 201 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in two equal annual installments beginning on February 11, 2024. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in two equal annual installments beginning on February 11, 2024. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2024 Filed Feb 13, 2024 17:15 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 201 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-004641 · form4.xml · nonDerivative · entry 1 DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,959.5491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 20:25 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 138 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003959 · form4.xml · derivative · entry 8 DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,178 Underlying: Common Stock · 138 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F7 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 7, 2024. F7 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 7, 2024. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 20:25 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 224 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003959 · form4.xml · derivative · entry 7 DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,316 Underlying: Common Stock · 224 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F7 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 7, 2024. F7 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 7, 2024. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 20:25 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 41 | $223.71 | $9,172.11 |
DisclosureSEC source: 0001127602-24-003959 · form4.xml · nonDerivative · entry 4 DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,758.5491 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 20:25 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 138 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-003959 · form4.xml · nonDerivative · entry 3 DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,799.5491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 20:25 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 78 | $223.71 | $17,449.38 |
DisclosureSEC source: 0001127602-24-003959 · form4.xml · nonDerivative · entry 2 DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,661.5491 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 20:25 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 224 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-003959 · form4.xml · nonDerivative · entry 1 DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,739.5491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 20:25 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantNon-qualified Stock Options · Derivative | 3,000 | $0.00 Strike: $222.28 | $0.00 |
DisclosureSEC source: 0001127602-24-003959 · form4.xml · derivative · entry 6 DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2034-02-05 F5 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F6 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 20:25 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 980 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003959 · form4.xml · derivative · entry 5 DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,540 Underlying: Common Stock · 980 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025. F3 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 6, 2025. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 02, 2024 Filed Feb 6, 2024 20:56 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 246 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003548 · form4.xml · derivative · entry 3 DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,560 Underlying: Common Stock · 246 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vested on February 2, 2024. F3 · derivative.expiration_date: The Restricted Stock Units vested on February 2, 2024. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 02, 2024 Filed Feb 6, 2024 20:56 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 85 | $221.54 | $18,830.90 |
DisclosureSEC source: 0001127602-24-003548 · form4.xml · nonDerivative · entry 2 DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,515.5491 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 02, 2024 Filed Feb 6, 2024 20:56 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 246 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-003548 · form4.xml · nonDerivative · entry 1 DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,600.5491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 13:34 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 64 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-029890 · form4.xml · derivative · entry 3 DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,806 Underlying: Common Stock · 64 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in two equal annual installments beginning on December 15, 2023. F4 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in two equal annual installments beginning on December 15, 2023. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Amount includes an additional 170 Restricted Stock Units resulting from the final adjustment ratio calculated pursuant to the terms of the Employee Matters Agreement by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 13:34 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 19 | $219.50 | $4,170.50 |
DisclosureSEC source: 0001127602-23-029890 · form4.xml · nonDerivative · entry 2 DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,354.5491 F3 · kind: Stock withholding to satisfy tax withholding obligations. F2 · balance_after: Amount includes 19.4137 shares acquired on May 31, 2023 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 13:34 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 64 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-029890 · form4.xml · nonDerivative · entry 1 DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,373.5491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · balance_after: Amount includes 19.4137 shares acquired on May 31, 2023 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| June 30, 2023 Filed Jul 6, 2023 00:01 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 3,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-020293 · form4.xml · derivative · entry 1 DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,700 Underlying: Common Stock · 3,036 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: In connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting restricted stock units ("RSUs") of Labcorp pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea (the "EMA"). The 2021 PSA was converted into a number of time-vesting Labcorp RSUs based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the adjustment ratio that applies to Labcorp equity awards in the Spin-Off, with vesting on the 30th day following Labcorp's filing of an annual report on Form 10-K that includes audited financial statements with respect to the 3-year period ending December 31, 2023. Amounts are estimates pending finalization of the adjustment ratio pursuant to the EMA. F2 · derivative.expiration_date: In connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting restricted stock units ("RSUs") of Labcorp pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea (the "EMA"). The 2021 PSA was converted into a number of time-vesting Labcorp RSUs based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the adjustment ratio that applies to Labcorp equity awards in the Spin-Off, with vesting on the 30th day following Labcorp's filing of an annual report on Form 10-K that includes audited financial statements with respect to the 3-year period ending December 31, 2023. Amounts are estimates pending finalization of the adjustment ratio pursuant to the EMA. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:41 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 370 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-015021 · form4.xml · derivative · entry 2 DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,664 Underlying: Common Stock · 370 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 7, 2024. F4 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 7, 2024. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:41 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantNon-qualified Stock Options · Derivative | 1,200 | $0.00 Strike: $223.86 | $0.00 |
DisclosureSEC source: 0001127602-23-015021 · form4.xml · derivative · entry 1 DiVincenzo Jonathan P. · CIK 0001453524 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,200 Underlying: Common Stock · 1,200 shares Expires 2033-05-04 F1 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F2 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.